Alternative Data for Lexeo Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 598 | Sign up | Sign up | Sign up |
| X Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 85 | Sign up | Sign up | Sign up |
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.
| Price | $6.31 |
| Target Price | Sign up |
| Volume | 408,060 |
| Market Cap | $461M |
| Year Range | $3.67 - $10.63 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 TranscriptFebruary 13 - SeekingAlpha |
 |
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in FebruaryFebruary 4 - Yahoo |
|
H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 ProgramFebruary 1 - Yahoo |
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsJanuary 27 - GlobeNewswire |
|
|
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 13 - SeekingAlpha |
|
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 13 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 530,000 | -530,000 | -20M | -20M | -0.330 |
| Q2 '25 | 0 | 510,000 | -510,000 | -26M | -26M | -0.600 |
| Q1 '25 | 0 | 500,000 | -500,000 | -33M | -32M | -0.990 |
| Q4 '24 | 1.9M | 0 | 970,000 | -26M | -25M | -0.780 |
| Q3 '24 | 0 | 510,000 | -510,000 | -29M | -29M | -0.890 |
Insider Transactions View All
| Adler Eric filed to sell 72,646 shares at $9.3. November 20 '25 |
| Robertson Jenny filed to sell 68,381 shares at $9.3. November 20 '25 |
| See Tai Sandi filed to sell 65,476 shares at $9.3. November 20 '25 |
| Townsend Richard Nolan filed to sell 240,991 shares at $9.3. November 20 '25 |
| Adler Eric filed to sell 73,261 shares at $9.6. October 17 '25 |
Similar companies
Read more about Lexeo Therapeutics (LXEO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Lexeo Therapeutics
The Market Cap of Lexeo Therapeutics is $461M.
Currently, the price of one share of Lexeo Therapeutics stock is $6.31.
The LXEO stock price chart above provides a comprehensive visual representation of Lexeo Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lexeo Therapeutics shares. Our platform offers an up-to-date LXEO stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Lexeo Therapeutics (LXEO) does not offer dividends to its shareholders. Investors interested in Lexeo Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Lexeo Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
